Search

Helpdesk

Sales contact

Home > eCOA consortium

eCOA consortium

Kayentis extends its contribution to scientific research in clinical trial endpoint assessment and joins the Critical Path Institute’s ePRO Consortium

eCOA consortium

Kayentis announces that it has joined the C-Path's ePRO Consortium, a nonprofit organization dedicated to advance the science of clinical trial endpoint assessment, and will contribute to the “eCOA Getting...

Follow us on social media

Subscribe to our newsletter

You may also like

Rare disease clinical research: it is time to tackle what...

The client’s voice: why they consistently choose Kayentis

Why you should join Kayentis

Rethinking pediatric clinical trials: guidelines from pediatric experts

Overcoming challenges in long-lasting pediatric clinical trials – Insights from...

Tackling the specificities of NASH/MASH clinical trials

About the author

Marc Chaperon

Estelle brings 20+ years of experience in pre-clinical and clinical research from Top 5 Pharma and Biotech firms. Leading projects across Phases 1 to 4 in diverse therapeutic areas, she offers deep insights into clinical science, operations, and regulatory intricacies. Appointed as Chief Medical Officer at Kayentis in May 2019.

Kayentis Europe
19 bis, chemin du vieux Chêne
38240 Meylan
France
Phone: +33 (0)4 76 00 54 20

Kayentis US
186 South Street
Suite 600
Boston, Massachusetts 02111
USA